Strokes and their relationship to hypertension

Current Opinion in Nephrology and Hypertension

Volumn 12, Issue 1, 2003, Pages 91-96

  Dickinson, C John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Haemorrhagic transformation; Ischaemic stroke pathology; Plasminogen activator therapy; Statin prophylaxis

Indexed keywords

ANTICOAGULANT AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTERY DIAMETER; ARTERY SPASM; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; HUMAN; HYPERTENSION; LUNG EMBOLISM; MORBIDITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ANTIHYPERTENSIVE AGENTS; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERTENSION;

EID: 0037225587     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200301000-00015     Document Type: Review

References (78)

1. Dickinson CJ. Why are strokes related to hypertension? Classic studies and hypotheses revisited. J Hypertens 2001; 19:1515-1521. A review providing the background to recent work relating hypertension to the common aetiology of cerebal haemorrhage and infarction.
2. Challa VR, Moody DM, Bell MA. The Charcot-Bouchard aneurysms controversy: impact of a new histologic technique. J Neuropathol Exp Neurol 1992; 51:264-271.
3. Tong DC, Adami A, Moseley ME, Marks MP. Prediction of hemorrhagic transformation following acute stroke: role of diffusion- and perfusion-weighted magnetic resonance imaging. Arch Neurol 2001; 58:587-593.
4. Nighoghossian N, Hermier M, Berthezene Y, et al. Early diagnosis of hemorrhagic transformation: diffusion/perfusion-weighted MRI versus CT scan. Cerebrovasc Dis 2002; 11:151-156. MRI adds extra weight to CAT scan in stroke diagnosis.
5. Lin DD, Filippi CG, Steever AB, Zimmerman RD. Detection of intracranial hemorrhage: comparison between gradient-echo images and b(0) images obtained from diffusion-weighted echo-planar sequences. Am J Neuroradiol 2002; 22:1275-1281.
6. Nighoghossian N, Hermier M, Adeleine P, et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2 weighted brain MRI study. Stroke 2002; 33:735-742.
7. Kidwell CS, Saver JL, Villablanca JP, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 2002; 33:95-98. UCLA experience in the detection of microbleeds before thrombolytic therapy. Detection of microbleeds is a signal that thrombolytic therapy is potentially dangerous.
8. Dubey N, Bakshi R, Wasay M, Dmochowski J. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimag 2002; 11:184-188.
9. Nakano S, Iseda T, Kawano H, et al. Hyperdensity on computed tomography after intra-arterial reperfusion acute middle cerebral artery occlusion: incidence and clinical significance. Stroke 2002; 32:2042-2048.
10. Fisher CM. Lacunes: small, deep cerebral infarcts. Neurology (Minneap) 1965; 15:774-784.
11. Dickinson CJ, Thomson AD. A post mortem study of the main cerebral arteries with special reference to their possible role in blood pressure regulation. Clin Sci 1960; 19:513-538.
12. Baker AB, Resch JA, Loewenson RB. Hypertension and cerebral atherosclerosis. Circulation 1969; 39:701-710.
13. Belichenko OI, Abramova NN, Arabidze GG, et al. Magnetic resonance tomography and magnetic resonance angiography in the clinical diagnosis of extra- and intracranial arterial pathology in patients with arterial hypertension [in Russian]. Vistnik Rentgenol Radiolog 1994; 3:25-28.
14. Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002; 33:21-25.
15. Staub F, Bogousslavsky J. Fatigue after stroke: a major but neglected issue. Cerebrovasc Dis 2001; 12:75-81. A useful reminder of a neglected topic.
16. Bondjers G, Glukhova M, Hansson GK, et al. Hypertension and atherosclerosis: cause and effect, or two effects with one unknown cause? Circulation 1991; 84 (Suppl. VI):VI-2-VI-16.
17. Chobanian AV. Vascular effects of systemic hypertension. Am J Cardiol 1992; 69:3E-7E.
18. Chobanian AV. The influence of hypertension and other hemodynamic factors in atherogenesis. Progr Cardiovasc Dis 1983; 26:177-196.
19. Hollander W, Prusty S, Kemper T, et al. The effects of hypertension on cerebral atherosclerosis in the cynomolgus monkey. Stroke 1993; 24:1218-1226.
20. Dickinson CJ. Neurogenic hypertension. London: Chapman and Hall; 1991.
21. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343:1179-1182.
22. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002; 33:862-875. A fully referenced up-to-date review of stroke prevention therapy in the light of recent work suggesting an inflammatory aetiology for atheroma, concentrating particularly on stroke prevention with statins, ACE inhibitors and vitamins.
23. Sironi L, Tremoli E, Miller I, et al. Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 2002; 32:753-760.
24. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
25. Ruilope LM, Schiffrin EL. Blood pressure control and benefits of antihypertensive therapy: does it make a difference which agents we use? Hypertension 2002; 38:537-542. Without coming to a final conclusion, the authors usefully review the preventive value of various hypotensive agents.
26. Klungel OH, Kaplan RC, Heckbert SR, et al. Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke 2002; 31:420-424. A contribution to the choice of hypotensive therapy, giving evidence for the greater protective benefit of thiazide diuretics compared with beta-blockers, calcium antagonists, and ACE inhibitors
27. Wang JG, Staessen JA. The benefit of treating isolated systolic hypertension. Curr Hypertens Rep 2001; 3:333-339.
28. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041. A well-designed trial based on intention-to-treat high-risk patients with cerebrovascular disease, which shows the benefit of lowering blood pressure
29. Hansson L. How far should we lower blood pressure in the elderly? Cardiovasc Drug Ther 2002; 15:275-279. A useful and wide-ranging discussion of many aspects of hypotensive protection in older people.
30. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drug Aging 2002; 18:151-164.
31. Voko Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34:1181-1185.
32. Corder R, Douthwaite JA, Lees DM, et al. Endothelin-1 synthesis reduced by red wine. Nature 2001; 414:863-864. A contribution to solving the 'French paradox'.
33. Tosaka M, Okajima F, Hashiba Y, et al. Sphingosine 1-phosphate contracts canine basilar arteries in vitro and in vivo: possible role in pathogenesis of cerebral vasospasm. Stroke 2002; 32:2913-2919.
34. Uhlmann D, Uhlmann S, Loffler BM, et al. Pharmacologic regulation of postischemic sinusoidal diameters in rats - a new approach for reducing hepatic ischemia/reperfusion injury. Clin Hemorheol Microcirc 2002; 24:233-246.
35. Pfister LA, Tureen JH, Shaw S, et al. Endothelin inhibition improves cerebral blood flow and is neuroprotective in pneumococcal meningitis. Ann Neurol 2002; 47:329-333.
36. Madonna P, de Stefano V, Coppola A, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33:51-56. Hyperhomocystinaemia was the only factor that identified young patients with ischaemic stroke.
37. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes are associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356:1949-1954.
38. De Leeuw PW, Birkenhager WH. The effects of calcium channel blockers on cardiovascular outcomes: a review of randomised controlled trials. Blood Press 2002; 11:71-78.
39. Paulson OB, Waldemar G. ACE inhibitors and cerebral blood flow. J Hum Hypertens 1990; 4 (Suppl. 4):69-72.
40. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N Engl J Med 1993; 328:907-913.
41. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan for Endpoint Reduction For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
42. Opie LH. Diuretic downsides - but in low doses they still seem among the best authenticated antihypertensives. Cardiovasc Drug Ther 2002; 14:407-409.
43. Klungel OH, Heckbert SR, Longstreth WT Jr, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med 2002; 161:37-43. See also Ref. [26].
44. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabet Care 2002; 24:2091-2096.
45. Opie LH, Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J Am Coll Cardiol 2002; 39:315-322.
46. Sleight P, Yusuf S, Pogue J, et al. Heart Outcomes Prevention Evaluation, HOPE. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2002; 358:2130-2131.
47. Keaney JF Jr. Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. Mol Aspect Med 2002; 21:99-166. A comprehensive and massive review of the pathogenetic sequence of atheroma formation and endothelial dysfunction.
48. Tegos TJ, Kalodiki E, Daskalopoulou SS, Nicolaides AN. Stroke: epidemiology, clinical picture, and risk factors - Part I of III. Angiology 2002; 51:793-808. A large review of the epidemiology of stroke and its risk factors.
49. Bots ML, Salonen JT, Elwood PC, et al. Gamma-glutamyltransferase and risk of stroke: the EUROSTROKE project. J Epidemiol Commun Health 2002; 56 (Suppl. 1):i25-i29.
50. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2002; 60:347-377. A comprehensive and important review of the use of this ADP receptor antagonist, which rates its protective effect as good as aspirin and also confers benefit in addition to that of aspirin, with fewer adverse events.
51. Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800-1806.
52. Hornung RS. Reducing cholesterol and atherosclerosis. Q J Med 2002; 95:339-341.
53. Ravnskov U. Is atherosclerosis caused by high cholesterol? Q J Med 2002; 95:397-403. A worthwhile review of the intellectual distance between cholesterol concentrations and the formation of atheroma.
54. MRC/BHF Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at risk of coronary heart death: early safety and efficacy experience. Eur Heart J 1999; 20:725-741.
55. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22. A large trial whose design was described in Ref. [54], with an unequivocal result showing that high-risk individuals taking 40 mg simvastatin a day obtain substantial and highly significant protection against strokes as well as heart attacks.
56. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:23-33. The other arm of Ref. [55], showing no benefit at all from antioxidant vitamin supplementation.
57. Alexandrov AV, Demchuk AM, Felberg RA, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2 MHz intracranial doppler monitoring. Stroke 2000; 31:610-614.
58. Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2002; 32:438-441. A useful discussion of the risk factors for stroke and the benefits of early thromboiytic therapy. See also Refs [60] and [65].
59. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke 2002; 33:493-496.
60. Saver JL, Kidwell CS, Starkman S. Commentary: thrombolysis in stroke: it works. BMJ 2002; 324:727-729. A strong rebuttal of the criticisms against the use of thrombolytic tPA therapy. See also Refs [58] and [65].
61. Madden K, Optimal timing of thrombolytic therapy in acute ischaemic stroke. CNS Drug 2002; 16:213-218.
62. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002; 33:717-724.
63. Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 2002; 32:399-404.
64. Adams HP Jr. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002; 33:856-861.
65. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the 'brain attack' campaign. BMJ 2002; 324:723-726. A strongly prejudiced argument against the use of a tPA thrombolytic agent, suggesting that it is over-promoted. See also Refs [58] and [60].
66. Grotta J, and the Combination Therapy Stroke Trial investigators. Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 2002; 12:258-263.
67. Reggiani A, Pietra C, Arban R, et al. The neuroproteotive activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging. Eur J Pharmacol 2002; 419:147-153.
68. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol (Regul Integr Compar Physiol) 2001; 281:R944-R950.
69. Montaner J, Alvarez-Sabin J, Molina CA, et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32:2762-2767.
70. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31:3034-3040.
71. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2002; 56:1015-1020.
72. Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. Brain Res - Brain Res Rev 2002; 36:23-34.
73. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2002; 32:2821-2827. Intravenous tPA is associated with early recanalization of occluded cerebral arteries causing stroke.
74. Kirsch T, Wellner M, Luft FC, et al. Altered gene expression in cerebral capillaries of stroke-prone spontaneously hypertensive rats. Brain Res 2002; 910:106-115.
75. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats. Hypertension 2002; 37:1388-1393.
76. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33:831-836.
77. Guerrini U, Sironi L, Tremoli E, et al. New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 2002; 33:825-830.
78. Tabuchi M, Umegaki K, Ito T, et al. Disturbance of circadian rhythm in heart rate, blood pressure and locomotive activity at the stroke-onset in malignant stroke-prone spontaneously hypertensive rats. Jap J Pharmacol 2002; 85:197-202.